Thymosin Alpha-1 Pharmacogenomics & Genetic Variability: What Your DNA Means for Immune Response
HealthRX.com
No DNA test currently guides thymosin alpha-1 use
Key numbers
- 45.8%HBeAg loss at 72 weeks with thymosin alpha-1 plus interferon, vs 28.0% on placebo, in hepatitis BSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
- 1,349 adultsAdults with chronic hepatitis B included in the 2026 Cochrane reviewSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
- 1.6 mgZadaxin label dose: subcutaneous or intramuscular, twice weekly for 4 weeksSource: fda.gov, as cited Nov 8, 2026
- 1.8 to 2.6 hoursHalf-life of thymosin alpha-1 in healthy volunteersSource: fda.gov, as cited Nov 8, 2026
See the public record for Thymalfasin
At a glance
- Drug / thymosin alpha-1 (thymalfasin), a 28-amino-acid synthetic peptide [2]
- Pharmacogenomic evidence / none found
- Genotype-based dosing / none identified; no US-approved dose exists [2]
- Pathway studied in the lab / Toll-like receptor 9 signaling in dendritic cells [1]
- Half-life / about 1.8 to 2.6 hours, no accumulation after five daily doses [2][4]
- US status / not FDA-approved; four orphan designations are not approvals [2]
- Best evidence for benefit / 2026 Cochrane review, very low certainty [5]
Does a person's DNA change how thymosin alpha-1 works?
We found no published study that genotyped people treated with thymosin alpha-1 and compared their outcomes by genotype, in hepatitis B or in any other condition. No variant has been shown to predict response. The FDA has not approved thymosin alpha-1 in the United States [2], and we found no genotype-based dosing recommendation from any regulator.
Questions worth asking
What the laboratory work shows
Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminal end; thymalfasin is the synthetic version with the same sequence [2]. It is described as an immune modulator that augments T-cell function [4].
Romani and colleagues reported that the peptide primes dendritic cells for antifungal T-helper type 1 resistance through Toll-like receptor 9 signaling. In murine dendritic cells it also induced indoleamine 2,3-dioxygenase; that activation required TLR9 and type I interferon receptor signaling and resulted in interleukin-10 production and regulatory T-cell generation [1]. A related review describes the peptide shaping effector and regulatory T-cell responses through innate immune receptors on dendritic cells [3]. That work maps a pathway a variant could act on; it did not measure genotypes in treated patients or tie a variant to clinical response.
What the trials show
The most comprehensive synthesis is a 2026 Cochrane review of 10 randomized trials and 1,349 adults with chronic hepatitis B, published between 1991 and 2018. It found possible lower all-cause mortality with thymosin alpha-1 (risk ratio 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) at very low certainty, and the reviewers said they are not sure the peptide helps [5].
In Lim and colleagues' double-blind trial, 98 adults received 24 weeks of lymphoblastoid interferon with thymosin alpha-1 (48 people) or placebo (50 people). HBeAg loss at 72 weeks was 45.8% versus 28.0% (difference 17.8%, 95% CI -1.2 to 35.3, P=0.067), which was not statistically significant [6].
Dose and regulatory status
In healthy volunteers, peak levels arrive about 0.7 to 2 hours after subcutaneous injection, with a half-life of about 1.8 to 2.6 hours and no accumulation after five daily doses [2][4]. No US-approved dose exists [2]. Italy's Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first influenza vaccination, repeated from week 8 to week 12 at the second [2].
Thymosin alpha-1 is not FDA-approved; its four US orphan drug designations come from a separate process and are not approvals [2]. FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no on December 4, 2024 on adding it to the pharmacy bulks list [7].
Frequently asked questions
Is there a genetic test for thymosin alpha-1?
Is thymosin alpha-1 FDA-approved?
Which immune pathway does the peptide act through?
What did the 2026 Cochrane review find?
References
Show all 7 referencesHide references
- Romani L, Bistoni F, Perruccio K, Montagnoli C, Gaziano R, Bozza S, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265-74.
- U.S. Food and Drug Administration.
- Pierluigi B, D'Angelo C, Fallarino F, Moretti S, Zelante T, Bozza S, et al. Thymosin alpha1: the regulator of regulators?. Ann N Y Acad Sci. 2010;1194:1-5.
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.
- Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11(2):245-53.
- U.S. Food and Drug Administration.